Ebb Therapeutics Appoints Elise Wilfinger as Chief Marketing Officer

PITTSBURGH, July 11, 2018 /PRNewswire/ -- Ebb Therapeutics, a medtech start-up initially focused on the development of innovative medical devices that help the millions of U.S. insomnia sufferers to more quickly find deeper, more restorative sleep, announced today the appointment of Elise Wilfinger as its Chief Marketing Officer. Wilfinger will commute between headquarters in Pittsburgh and her home office in Ridgefield, CT.

Wilfinger will oversee brand strategy, positioning and narrative development, consumer demand generation, experience and adoption and all surround-sound marketing, as the company's first product is launched to consumers. She will also have strategic oversight for growing the company's industry profile and reputation.

She brings over 20 years of business strategy and media experience, most recently as EVP, Corporate Strategy & Brand Officer at The Mars Agency, a full-service, global shopper marketing agency, where she was responsible for agency branding, PR, corporate communications and new and organic growth development.

Prior to joining The Mars Agency, Wilfinger was Chief Strategy Officer and COO at Home Team Marketing, a New York media company that connects national brands with local families and high school students. As Ryan Partnership's first Chief Marketing Officer and Senior Partner, she led brand and growth strategy efforts to help the firm become the largest, independent, full-service agency network in North America.

"We're thrilled Elise has joined our executive leadership team," said Don Spence, President & CEO of Ebb Therapeutics. "Her expertise in brand development, lead generation and loyalty marketing will help us evolve our business model, accelerate our long-term, domestic and international marketing strategy and build relevant products for consumers today and tomorrow."

Wilfinger also led large agency teams at McCann Relationship Marketing, Digitas and Ogilvy & Mather Direct, providing strategy, creative inspiration and account leadership for clients, primarily in the health, financial services and CPG verticals.

"It's a very exciting time to join this team," said Wilfinger. "Ebb Therapeutics is a leader in FDA-cleared, insomnia devices, and we're on the verge of launching these into the consumer market. In the future, we plan to further leverage our technologies to solve other global, health crises that affect women, men and possibly children. I'm proud to share my experience and ideas to help further drive the company's consumer relevance and growth."

About Ebb Therapeutics
Headquartered in Pittsburgh, PA, the privately held company was founded in 2008 by Eric Nofzinger, M.D., after he performed pioneering brain imaging studies on patients with insomnia at the University of Pittsburgh. His research resulted in the development of Ebb Insomnia Therapy, a clinically safe, medical grade device, with none of the side effects found in traditional insomnia treatments. Ebb Therapeutics was funded in part by a grant from the National Institutes of Health, as well as by private equity and venture capital firms, KKR, Arboretum Ventures, Versant Ventures and Partner Ventures.

To learn more about Ebb Therapeutics, please visit http://www.ebbsleep.com.

For more information, contact:
Elise Wilfinger
Ebb Therapeutics
203.247.7420

SOURCE Ebb Therapeutics

Related Links

https://ebbsleep.com